The International Collaboration on Cosmetics Safety enters a new chapter with the appointment of its 2026 Board officers, reinforcing its global commitment to advancing animal-free approaches in cosmetics safety science at a time of rapid regulatory and scientific change.
The International Collaboration on Cosmetics Safety (ICCS) has finalized its 2026 Board officers following elections conducted during the organization’s December 2025 Board meeting, marking a key step for this relatively young global initiative as it strengthens its role in advancing scientifically rigorous, human-relevant alternatives to animal testing in cosmetics safety evaluation. The newly appointed leadership highlights both consistency and the organization’s increasing maturity, building on a year of notable achievements while preparing to broaden its influence across regulatory, scientific, and industry spheres worldwide.
ICCS works at the nexus of science, policy, and collective action, uniting a broad array of stakeholders who pursue a shared mission: advancing the worldwide integration and recognition of animal-free safety science for cosmetics and their components. The appointment of the 2026 Board officers highlights the organization’s commitment to preserving a strategic trajectory while navigating an increasingly intricate global environment, where expectations surrounding ethical research, scientific robustness, and regulatory coherence are continually shifting.
Ongoing leadership stability and broad international representation
The 2026 Board leadership brings together senior figures from across the cosmetics, consumer products, and regulatory advocacy sectors, reflecting the multi-stakeholder nature that has defined ICCS since its inception. Stéphane Dhalluin, Ph.D., DABT, Global Head of Human & Environmental Safety Evaluation at L’Oréal, has been re-elected as Chair of the Board of Directors. His reappointment signals confidence in a leadership approach that has emphasized scientific credibility, global cooperation, and constructive engagement with regulators.
Serving alongside him as Vice Chair is Darren Praznik, President and Chief Executive Officer of Cosmetics Alliance Canada, whose long-standing work in industry advocacy and regulatory engagement provides a strong regional and policy-driven outlook. The role of Secretary will be fulfilled by Heike Scheffler, Ph.D., Safety Advocacy and Regulatory Toxicology Director for Global Product Stewardship in Beauty and Oral Care at Procter & Gamble, bringing broad expertise in regulatory toxicology and global product safety systems. Michael Southall, Ph.D., Senior Director and Head of Global Toxicology and Clinical Safety within Medical Clinical & Safety Sciences at Kenvue, has been appointed Treasurer, offering substantial leadership experience in toxicology and governance.
Acting collectively, the officers make up a Board leadership team whose experience extends across multinational corporations, industry groups, and regulatory science, strengthening ICCS’ role as a neutral forum for cooperation rather than an advocate for any particular sector. This equilibrium underpins the organization’s credibility, especially as it works to shape regulatory perspectives and promote alignment on animal-free safety approaches.
Driving the progress of animal-free science through collective collaboration
At the heart of ICCS’ mission is the belief that animal-free approaches to safety assessment are not only ethically preferable but scientifically superior when properly developed and validated. Since its formation in early 2023, ICCS has worked to demonstrate that non-animal methods can provide reliable, relevant information for protecting both human health and the environment. The confirmation of the 2026 Board officers comes at a moment when this message is gaining traction, supported by tangible outputs and growing engagement from regulators around the world.
Throughout 2025, ICCS introduced a range of initiatives that reinforced its scientific framework and broadened its reach. Among these efforts was the publication of a Best Practice Guidance document, created to enhance clarity and uniformity in how animal-free safety assessment methods are applied. This guidance sought to close gaps between scientific progress and regulatory requirements, delivering a practical reference that stakeholders could use when generating or reviewing non-animal data.
In parallel, ICCS contributed to the creation of innovative methodologies aligned with next generation risk assessment (NGRA), an evolving framework that combines cutting-edge in vitro, in silico, and exposure-driven techniques. These methods are increasingly recognized as vital to contemporary toxicology, providing the possibility of more human-relevant insights while decreasing dependence on animal studies. ICCS’ work in this area underscores its dedication to promoting ethical progress as well as scientific rigor.
Equally important has been the organization’s emphasis on dialogue. Throughout 2025, ICCS engaged extensively with regulators, scientists, and policymakers across multiple regions, contributing to discussions on how animal-free data can be interpreted and accepted within existing regulatory frameworks. These conversations have been instrumental in building shared understanding and trust, particularly in jurisdictions where regulatory acceptance of non-animal methods is still developing.
A pivotal moment for cosmetics safety regulation
The installation of the 2026 Board officers unfolds amid a period of substantial shifts in global cosmetics regulations, as numerous markets revisit long‑established testing protocols in light of public expectations, scientific progress, and emerging international policy directions, and within this evolving landscape, organizations such as ICCS remain essential in coordinating innovation with regulatory demands so that advancement stays both trustworthy and sustainable.
ICCS leadership has consistently emphasized that the transition to animal-free safety science cannot be achieved through isolated efforts. Instead, it requires coordinated action across industry, academia, regulators, and civil society. The composition of the Board reflects this philosophy, bringing together leaders who understand the technical, regulatory, and organizational dimensions of change.
Statements from ICCS leadership following the elections highlighted both confidence and realism. While there is recognition of the momentum generated in recent years, there is also acknowledgment that significant work remains. Achieving widespread regulatory acceptance of animal-free approaches will require continued investment in research, transparent data sharing, and ongoing engagement with authorities to address legitimate questions around reliability, applicability, and protection of public health.
The re-elected Chair highlighted how crucial it is to draw on ICCS’ global, multi-stakeholder framework to narrow the distance between innovation and regulation, ensuring that progress in animal-free science moves beyond laboratories and becomes reliable, consistently applied tools that regulators can confidently use.
Strengthening foundations for long-term impact
As ICCS looks ahead to 2026 and beyond, the organization is focused on consolidating its achievements while expanding its reach. The newly confirmed Board leadership is expected to play a central role in shaping priorities that balance scientific ambition with practical implementation. This includes identifying areas where additional guidance or consensus-building is needed, supporting the validation and communication of new methodologies, and fostering international alignment to reduce fragmentation in regulatory requirements.
Education continues to be a central pillar of ICCS’ strategy, with the organization striving to offer accessible, science‑grounded materials and spaces for dialogue that help clarify the principles of animal‑free safety science and support well‑informed choices. This effort becomes especially vital in a field where misunderstandings or uneven levels of expertise can hinder advancement, even when the science itself is robust.
The organization’s structure, which includes market-leading cosmetics and ingredient manufacturers, trade and research associations, and animal protection organizations, positions it uniquely to address these challenges. This diversity of perspectives helps ensure that discussions remain grounded, balanced, and focused on shared goals rather than narrow interests.
Headquartered in New York, ICCS continues to operate as a global initiative, reflecting the inherently international nature of cosmetics development and regulation. Products and ingredients often move across borders, making harmonization and mutual recognition of safety approaches increasingly important. Through its collaborative model, ICCS seeks to contribute to this harmonization, reducing duplication and fostering trust in animal-free science worldwide.
In confirming its 2026 Board officers, ICCS conveys steadiness while signaling continued progress, with its leadership team offering consistent guidance after a year of tangible accomplishments and the seasoned insight required to steer the upcoming phase of transformation; as scientific advances accelerate and regulatory expectations shift, the organization’s function as a convening force and driving agent for animal-free cosmetics safety science is poised to gain even greater significance.
In the end, the importance of the 2026 Board elections stems not only from the members selected but also from what their leadership conveys: an ongoing dedication to cooperation, scientific rigor, and the responsible evolution of alternatives to animal testing. For ICCS and its stakeholders, the years ahead present a chance to turn vision into enduring results, shaping the future of cosmetics safety in a manner that brings ethics, science, and global public confidence into alignment.
